Fig. 5
Augmented antitumor lymphocyte activation in unirradiated tumors by PRT + αPD1 compared to XRT + αPD1. A UMAP color-coded for lymphocyte activation markers in unirradiated tumors subjected to various combination therapies involving NBTXR3, XRT, PRT, and αPD1. B The expression level of antitumor lymphocyte activation markers in cytotoxic lymphocytes. The expression levels of activation markers were analyzed using the Kruskal–Wallis test. A p-value of < 0.05 was deemed statistically significant. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. NS, not significant